RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
直肠癌放化疗期间 TIL（肿瘤浸润淋巴细胞）与炎症血液因子的变化
英文原题：Changes in Tumor-Infiltrating Lymphocytes and Inflammatory Blood Factors during Chemoradiation Therapy in Rectal Cancer.
查看英文原题
Changes in Tumor-Infiltrating Lymphocytes and Inflammatory Blood Factors during Chemoradiation Therapy in Rectal Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
研究提示，治疗后立即出现的 CD4+ TILs 变化以及治疗期间炎症血液指标的变化，可能有助于预测肿瘤退缩率和 TRG。
中文摘要
方法
回顾性研究纳入 196 例晚期直肠癌患者，他们在接受 nCRT 后进行根治性切除。研究者对 nCRT 前及治疗期间活检标本中的淋巴细胞表面标志物（包括 CD3、CD4 和 CD8）进行免疫组化染色。治疗前和 nCRT 开始后第 7 天采血，评估血液炎症因子。
结果
CD4 水平变化与 TRG 相关。nCRT 期间 NLR 和 SII 与 TRG 相关。指标低于截断值的患者，TRG 趋势上较好。nCRT 期间 NLR 以及 NLR、PLR 和 SII 的变化与肿瘤缩小率相关。PLR 变化与 TRG 相关。TIL、外周血指标变化与复发率无关。
结论
治疗刚开始后 CD4⁺ TIL 的变化以及治疗期间血液炎症因子的变化，可能有助于预测肿瘤缩小率和 TRG。这些变化在治疗早期即出现，可能用于预测疗效。
展开英文摘要原文
METHODS
We retrospectively studied 196 patients with rectal cancer who underwent curative resection after nCRT for advanced rectal cancer. Immunohistochemical staining of lymphocyte surface markers, including CD3, CD4, and CD8, was performed on biopsy specimens before and during nCRT. Inflammatory blood factors were assessed using blood samples collected before treatment and 7 days after the initiation of nCRT.
RESULTS
Changes in CD4 levels were related to TRG. NLR, and SII during nCRT were associated with TRG. TRG tended to be better in patients with values below the cutoff. The NLR during nCRT and changes in NLR, PLR, and SII were associated with the tumor shrinkage rate. Changes in PLR were related to TRG. There was no relationship between TIL, peripheral blood changes, and recurrence rate.
CONCLUSION
It was suggested that changes in CD4+ TILs immediately after treatment initiation and changes in inflammatory blood factors during treatment may be useful for predicting the reduction rate and TRG. These changes begin early during treatment and may be useful in predicting efficacy.
论文信息
- 作者
- Miyakita H、Ogimi T、Kayano H、Mori M、Yamamoto S
- 单位
- Department of Surgery, Tokai University School of Medicine, Isehara, Japan, hmiyakita0124@gmail.com.Japan
- 期刊
- Oncology2026
- 原文标识
- PubMed 40159232 · DOI 10.1159/000545312